FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Lymphoma Treatment
The cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers.
Bristol Myers Squibb (BMS) announced on Feb. 5, 2021 that FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel), BMS’ chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
According to a BMS company press release, the cell therapy will be manufactured for each individual patient at BMS’ immunotherapy manufacturing facility in Bothell, WA, and will be launched across a network of treatment centers.
“Breyanzi, a CAR T cell therapy, will have an important role in clinical practice, offering people living with relapsed or refractory large B-cell lymphoma the chance for sustained response with an individualized treatment experience,” said Samit Hirawat, MD, chief medical officer, Bristol Myers Squibb, in the press release. “Today’s FDA approval reflects our deep commitment to advancing cell therapy research, developing innovative treatments, and supporting patients at every step of their treatment journey.”
Source: BMS
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
